

Aalborg Universitet

Bioactive compounds of elder (Sambucus nigra L.) with focus on their potential antidiabetic effects

Christensen, Lars Porskjær; Christensen, Kathrine Bisgaard; Fretté, Xavier

Published in: First International Symposium on Elderberry

Publication date: 2013

Document Version Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):

Christensen, L. P., Christensen, K. B., & Fretté, X. (2013). Bioactive compounds of elder (*Sambucus nigra* L.) with focus on their potential anti-diabetic effects. In A. L. Thomas, D. Charlebois, C. M. Greenlief, P. L. D. Vincent, K. L. Fritsche, & K. Kaack (Eds.), *First International Symposium on Elderberry* (pp. 25)


General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
 You may not further distribute the material or use it for any profit-making activity or commercial gain
 You may freely distribute the URL identifying the publication in the public portal -

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

First International Symposium on ELDERBERRY



PROCEEDINGS

Stoney Creek Inn • Columbia, Missouri USA
June 9-14, 2013

Bioactive Compounds of Elder (Sambucus nigra L.) with Focus on their Potential Anti-diabetic Effects

Lars Porskjær Christensen, Kathrine Bisgaard Christensen, and Xavier Christian Fretté

University of Southern Denmark, Denmark

Preparations of elder (*Sambucus nigra*) are used in traditional medicine as diuretics and to treat colds, influenza, inflammation, and diabetes. Elderberries and elderflowers are rich in polyphenols such as phenolic acids, flavonol glycosides, and anthocyanins. Polyphenols are known for their antioxidant activity and are believed to prevent oxidative stress, a condition that may lead to serious diseases such as cancer, cardiovascular diseases, inflammation and type-2 diabetes (T2D). Hence, polyphenols have been pointed out as beneficial agents in both elderflowers and elderberries. Epidemiological investigations tend to confirm the protective effects of polyphenols against cardiovascular diseases and T2D but the mechanisms by which they exert their protective effects are far from understood. The reported beneficial effects of polyphenols against cancers and inflammation are mainly based on *in vitro* studies. The disparity between an excellent *in vitro* activity related to a specific disease(s) and a weaker *in vivo* effect of polyphenols may be due to pharmacokinetic properties such as poor bioavailability, low absorbability, and/or metabolism. Therefore the health effects of elder could be due to (1) polyphenols whose modes of action differ from the traditional one proposed for exogenous antioxidants or (2) other types of biomolecules not identified yet.

Extracts of elderflowers have been found to exert insulin-like and insulin-releasing actions in vitro and to activate PPARy as well as to stimulate insulin-dependent glucose uptake. This indicates that elderflowers may be used in the prevention and/or treatment of insulin resistance. In the search for an explanation of the anti-diabetic effects of elderflowers we undertook an investigation of a methanol extract of elderflowers. A bioassay-guided fractionation of the extract by reverse phase flash column chromatography and semipreparative HPLC resulted in the isolation of several compounds being able to activate PPARy, including linoleic acid and linolenic acid, and the flavanone aglycone naringenin. However, major elderflower metabolites such as quercetin-3-O-rutinoside, quercetin-3-O-glucoside, kaempferol-3-O-rutinoside, isorhamnetin-3-O-rutinoside, isorhamnetin-3-O-glucoside, and 5-Ocaffeoylquinic acid were unable to activate PPARy in vitro. Several compounds with structures similar to that of naringenin have been identified previously as activators and/or agonists of PPARy. These include among others the flavonol aglycone kaempferol, which indicates that flavonoid aglycones are relatively good ligands for PPARy in contrast to their respective glycosides. Further investigations are, however, needed to demonstrate the bioavailability, absorption, and metabolism of elderflower flavonoids in order to determine their potential anti-diabetic or other health-promoting effects.